Loading...

Ligand Pharmaceuticals Incorporated

LGND•NASDAQ
Healthcare
Biotechnology
$231.27
$2.79(1.22%)
U.S. Market opens in 49h 27m

Ligand Pharmaceuticals Incorporated (LGND) Stock Overview

Explore Ligand Pharmaceuticals Incorporated’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap4.6B
P/E Ratio36.36
EPS (TTM)$6.13
ROE0.14%
Fundamental Analysis

AI Price Forecasts

1 Month$189.99
3 Months$199.93
1 Year Target$137.82

LGND Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Ligand Pharmaceuticals Incorporated (LGND) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 65.46, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $137.82.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 36.36 and a market capitalization of 4.6B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
1.22%
5-Day Change
2.33%
1-Month Change
14.68%
3-Month Change
14.97%
6-Month Change
23.69%
Year-to-Date (YTD) Change
22.32%
1-Year Change
113.05%
3-Year Change
199.30%
5-Year Change
53.15%
All-Time (Max) Change
404.39%

Contact Information

https://www.ligand.com
858 550 7500
5980 Horton Street, Jupiter, CA, 94608

Company Facts

68 Employees
IPO DateNov 18, 1992
CountryUS
Actively Trading

Frequently Asked Questions